I. Grimmelmann

发表

Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG

M. Weichenthal, J. Utikal, S. Haferkamp, 2022, Journal for ImmunoTherapy of Cancer.

Checkpoint inhibitor–induced autoimmune central nervous system disorder in patients with metastatic melanoma and Hodgkin’s lymphoma

R. Gutzmer, M. Stangel, T. Skripuletz, 2021, Clinical and Experimental Neuroimmunology.

Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade

R. Gutzmer, S. Steffens, S. Heinemann, 2022, Oncology.

Sirolimus diminishes the expression of GRO-α (CXCL-1) /CXCR2 axis in human keratinocytes and cutaneous squamous cell carcinoma cells.

R. Gutzmer, I. Grimmelmann, K. Schaper-Gerhardt, 2021, Journal of dermatological science.

Case Report: Sustained Remission Due to PD-1-Inhibition in a Metastatic Melanoma Patient With Depleted B Cells

J. Becker, R. Gutzmer, Lena M. Wulfken, 2021, Frontiers in Immunology.

MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.

M. Weichenthal, J. Utikal, S. Haferkamp, 2022, European journal of cancer.

Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.

J. Utikal, C. Berking, K. Kähler, 2021, European journal of cancer.

787O Adjuvant immunotherapy with nivolumab (NIVO) versus observation in completely resected Merkel cell carcinoma (MCC): Disease-free survival (DFS) results from ADMEC-O, a randomized, open-label phase II trial

A. Hauschild, S. Haferkamp, D. Schadendorf, 2022, Annals of Oncology.

Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma: A Series of 12 Patients

R. Gutzmer, J. Hassel, M. Sachse, 2022, Cancers.

Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany

M. Weichenthal, J. Utikal, C. Berking, 2022, Cancers.

Psoriasis vulgaris triggered by treatment with mogamulizumab in a patient with cutaneous T‐cell lymphoma

R. Gutzmer, V. Schacht, I. Grimmelmann, 2021, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG

M. Weichenthal, J. Utikal, S. Haferkamp, 2023, Journal for ImmunoTherapy of Cancer.

Monocyte chemoattractant protein 1 as a potential biomarker for immune checkpoint inhibitor‐associated neurotoxicity

R. Gutzmer, T. Wirth, H. Tumani, 2023, Cancer medicine.

Immune checkpoint inhibition and targeted therapy for melanoma: A patient‐oriented cross‐sectional comparative multicentre study

S. Haferkamp, M. Gaiser, R. Gutzmer, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

J. Utikal, A. Hauschild, S. Haferkamp, 2023, The Lancet.